DNLI - デナリ・セラピュ―ティクス (Denali Therapeutics Inc.) デナリ・セラピュ―ティクス

 DNLIのチャート


 DNLIの企業情報

symbol DNLI
会社名 Denali Therapeutics Inc (デナリ・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 デナリ・セラピューティクス(Denali Therapeutics Inc.)はバイオテクノロジー企業である。同社は、アルツハイマー病、パーキンソン病、筋萎縮性側索硬化症(ALS)などの神経変性疾患患者の治療法の発見と開発に従事する。同社は、遺伝的原因及び神経変性疾患の根底にある生物学的プロセスに関する科学的な洞察に基づいて、治療薬の多様なポートフォリオを開発する。同社は、脱遺伝子遺伝子(変異した場合に神経変性疾患を引き起こす遺伝子)、欠陥細胞内輸送、グリア機能障害および軸索変性を含む、神経変性のトリガーまたはエフェクターとして関与する約4つの特異的経路を選択した。同社の開発プログラムには、リソソーム機能経路、グリア細胞生物学的経路、および細胞恒常性経路が含まれる。同社の製品パイプラインには、DNL201、DNL 151、ATV:aSyn、ETV:IDS、DNL747、ATV:TREM2などの薬物候補が含まれる。   デナリ・セラピュ―ティクスは米国のバイオ医薬品会社。アルツハイマ―病、パ―キンソン病、筋萎縮性側索硬化症(ALS)などに代表される神経変性疾患に対する治療薬の発見・開発に従事。疾患の原因やリスク要因に直接対処することを目指し、6つの異なるプログラムで臨床開発及び臨床前開発に取り組む。本社はカリフォルニア州サウス・サンフランシスコ。   Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco.
本社所在地 151 Oyster Point Blvd. 2nd Floor South San Francisco CA 94080 USA
代表者氏名 Marc Tessier-Lavignec マルクテッシーエ - ラヴィーニェック
代表者役職名 Chairman of the Board Co-Founder
電話番号 +1 650-866-8548
設立年月日 41548
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数 130人
url www.denalitherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/dnli
adr_tso
EBITDA EBITDA(百万ドル) -124.66400
終値(lastsale) 18.34
時価総額(marketcap) 1738762415.74
時価総額 時価総額(百万ドル) 1690.411
売上高 売上高(百万ドル) 2.28900
企業価値(EV) 企業価値(EV)(百万ドル) 1317.82
当期純利益 当期純利益(百万ドル) -123.13300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Denali Therapeutics Inc revenues increased from $0K to $2.3M. Net loss increased 80% to $78.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research_Development Expense - Balanci increase of 89% to $68.7M (expense) Stock-based Compensation in R&D increase from $1.2M to $4.3M (expense) Selling.

 DNLIのテクニカル分析


 DNLIのニュース

   Denali Therapeutics Announces Presentations on DNL310 (ETV:IDS) Development Program in MPS II (Hunter Syndrome) at the Upcoming WORLDSymposium™  2022/02/01 14:00:00 Benzinga
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI ), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced upcoming presentations from the DNL310 (ETV:IDS) clinical development program to be given at the 18 th Annual WORLD Symposium ™, which will be held February 7-11, 2022, in San Diego, California, and virtually. DNL310 is an investigational brain-penetrant enzyme replacement therapy intended to treat both central nervous system (CNS) and peripheral manifestations of MPS II (Hunter syndrome). An oral presentation will provide longer-term safety, biomarker (glycosaminoglycans and lysosomal lipids) and exploratory clinical data on Cohorts A and B from an ongoing Phase 1/2 clinical trial of DNL310 in MPS II. A poster presentation will provide details on a planned, potentially registrational Phase 2/3 clinical trial of DNL310 in MPS II.
   Parkinson''s Disease Pipeline Offers Promising New Options for Treatment | DelveInsight  2022/01/18 01:00:00 Benzinga
Los Angeles, USA, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Parkinson''s Disease Pipeline Offers Promising New Options for Treatment | DelveInsight DelveInsight''s "Parkinson''s Disease Pipeline Insight" report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the Parkinson''s Disease pipeline landscapes. The report comprises Parkinson''s Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Parkinson''s Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Parkinson''s Disease pipeline products. Some of the key takeaways from the Parkinson''s Disease Pipeline Report Major Parkinson''s Disease companies such as Cerevel Therapeutics, Abbvie, Pharma Two B, Roche, Kissei Pharmaceutical, Peptron, Inc., Lundbeck A/S, AstraZeneca, Nobilis Therapeutics, Treefrog Therapeutics, Cantabio Pharmaceuticals, Anavex Life Sciences, Ipsen, Prevail Therapeutics, AFFiRiS, Sio Gene Therapies, UCB Pharma, Brain Neurotherapy Bio, Inc., Neuraly, Inc., NeuroDerm, BlueRock Therapeutics, Sun Pharma Advanced Research Company, Xoc Pharmaceuticals, Hong Kong WD Pharmaceutical, 1ST Biotherapeutics, Inc., Biogen, Denali Therapeutics, Inhibikase Therapeutics,Cerevance, Aspen Neuroscience,Prilenia Therapeutics,Cortexyme Inc.,Gain Therapeutics, Clexio Biosciences, Orpheris, Inc., Alkahest, Inc., and others are developing potential drug candidates to improve the Parkinson''s Disease treatment scenario.
   G Medical, ChemoCentryx top healthcare gainers; Denali, Immix among losers  2022/01/13 15:02:19 Seeking Alpha
G Medical Innovations (GMVD) +20%. ChemoCentryx (CCXI) +12%. Denali Therapeutics Inc. (DNLI) -13%. Immix Biopharma (IMMX) -11%.
   Denali Therapeutics falls on clinical hold for Alzheimers candidate (NASDAQ:DNLI)  2022/01/13 13:19:02 Seeking Alpha
Denali Therapeutics (DNLI) is trading ~13.9% lower in the pre-market after announcing a clinical hold imposed by the FDA for the companys experimental therapy for Alzheimers
   Denali Therapeutics Inc Shares Approach 52-Week Low - Market Mover  2022/01/10 05:03:34 Kwhen Finance
Denali Therapeutics Inc (DNLI) shares closed today at 1.7% above its 52 week low of $40.87, giving the company a market cap of $5B. The stock is currently down 6.8% year-to-date, down 48.1% over the past 12 months, and up 93.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 28.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -46.3% The company's stock price performance over the past 12 months lags the peer average by 257.5% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -171.0% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Denali Therapeutics (NASDAQ:DNLI) Hits New 52-Week Low on Insider Selling  2021/12/07 06:20:45 Dakota Financial News
Denali Therapeutics Inc. (NASDAQ:DNLI)s share price reached a new 52-week low on Monday after an insider sold shares in the company. The stock traded as low as $41.12 and last traded at $42.45, with a volume of 2828 shares changing hands. The stock had previously closed at $42.59. Specifically, CEO Ryan J. Watts sold 18,333 []
   Aziyo Biologics (NASDAQ:AZYO) & Denali Therapeutics (NASDAQ:DNLI) Financial Contrast  2021/12/06 07:32:42 ETF Daily News
Aziyo Biologics (NASDAQ:AZYO) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership. Risk and Volatility Aziyo Biologics has a beta of 0.56, indicating that its stock price is [] The post Aziyo Biologics (NASDAQ:AZYO) & Denali Therapeutics (NASDAQ:DNLI) Financial Contrast appeared first on ETF Daily News .
   Denali Therapeutics Inc. (NASDAQ:DNLI) CEO Sells $823,518.36 in Stock  2021/12/05 09:46:41 Dakota Financial News
Denali Therapeutics Inc. (NASDAQ:DNLI) CEO Ryan J. Watts sold 18,333 shares of the companys stock in a transaction dated Wednesday, December 1st. The stock was sold at an average price of $44.92, for a total value of $823,518.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be []
   Denali Therapeutics Inc (DNLI) President and CEO Ryan J. Watts Sold $823,518 of Shares  2021/12/04 00:15:02 GuruFocus
Related Stocks: DNLI ,
   Polianta Ltd Buys Shares of 19,800 Denali Therapeutics Inc. (NASDAQ:DNLI)  2021/11/30 14:52:42 Dakota Financial News
Polianta Ltd bought a new stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 19,800 shares of the companys stock, valued at approximately $998,000. Other large investors also recently bought and sold shares of the company. AXA []
   Denali Therapeutics (DNLI) Presents At Goldman Sachs 42nd Annual Global Healthcare Conference - Slideshow  2021/06/10 19:11:20 Seeking Alpha
   Denali Therapeutics Inc (DNLI): Price Now Near $70.67; Daily Chart Shows Downtrend on 100 Day Basis  2021/06/08 15:09:35 ETF Daily News
Regarding the trend, note that the strongest trend exists on the 50 day timeframe. The post Denali Therapeutics Inc (DNLI): Price Now Near $70.67; Daily Chart Shows Downtrend on 100 Day Basis appeared first on ETF Daily News .
   Denali Therapeutics (DNLI ) Presents At 2021 Jefferies Virtual Healthcare Conference - Slideshow  2021/06/03 00:19:31 Seeking Alpha
   Denali Therapeutics (DNLI) Presents At UBS 2021 Global Healthcare Virtual Conference - Slideshow  2021/05/25 19:18:34 Seeking Alpha
   Tao Capital Management LP Buys Denali Therapeutics Inc, Sells Tesla Inc, Uber Technologies Inc, ...  2021/05/18 18:38:33 GuruFocus
Related Stocks: DNLI ,

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 デナリ・セラピュ―ティクス DNLI Denali Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)